Evidence map›Paper›PMID 34821362›Full record

ArticleBioscience reports2021

LncRNA SNHG6 knockdown inhibits cisplatin resistance and progression of gastric cancer through miR-1297/BCL-2 axis.

Jiazhan Mei, Guiju Liu, Ruijun Li, Peng Xiao, Dan Yang, Hua Bai, Yibin Hao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioscience reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. The Functions and Mechanisms of Long Non-coding RNA SNHGs in Gastric Cancer.Combinatorial chemistry & high throughput screening · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jiazhan MeiDepartment of Oncology, People's Hospital of Zhengzhou Affiliated to Southern Medical University, Zhengzhou, Henan, China.
Guiju LiuDepartment of Oncology, People's Hospital of Zhengzhou Affiliated to Southern Medical University, Zhengzhou, Henan, China.
Ruijun LiDepartment of Oncology, People's Hospital of Zhengzhou Affiliated to Southern Medical University, Zhengzhou, Henan, China.
Peng XiaoDepartment of Oncology, People's Hospital of Zhengzhou Affiliated to Southern Medical University, Zhengzhou, Henan, China.
Dan YangDepartment of Oncology, People's Hospital of Zhengzhou Affiliated to Southern Medical University, Zhengzhou, Henan, China.
Hua BaiDepartment of Oncology, People's Hospital of Zhengzhou Affiliated to Southern Medical University, Zhengzhou, Henan, China.
Yibin HaoDepartment of Oncology, People's Hospital of Zhengzhou Affiliated to Southern Medical University, Zhengzhou, Henan, China.ORCID 0000-0002-8964-8246
Zhengzhou People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin (DDP) resistance is a huge obstacle to gastric cancer (GC) treatment. Long non-coding RNAs (lncRNAs) have been manifested to exert pivotal functions in GC development. Herein, we aimed to explore the functional impact of lncRNA small nucleolar RNA host gene 6 (SNHG6) on DDP resistance and progression of GC. Quantitative real-time PCR (qRT-PCR) assay or Western blotting was performed to detect the expression of SNHG6, microRNA(miR)-1297, and epithelial-mesenchymal transition (EMT)-related factors and B-Cell Lymphoma 2 (Bcl-2) in DDP-resistant GC cells. Half inhibition concentration (IC50) to DDP, clonogenicity, apoptosis and invasion were examined via CCK-8 assay, colony formation assay, flow cytometry and Transwell assay, respectively. Target association between miR-1297 and SNHG6 or BCL-2 was demonstrated via dual-luciferase reporter assay or RIP assay. Xenograft models in nude mice were formed to investigate role of SNHG6 in vivo. We found that SNHG6 and BCL-2 were up-regulated, while miR-1297 expression was declined in GC tissues and DDP-resistant cells. Moreover, depletion of SNHG6 or gain of miR-1297 could repress DDP resistance, proliferation and metastasis of DDP-resistant cells, which was weakened by miR-1297 inhibition or BCL-2 overexpression. Besides, SNHG6 positively regulated BCL-2 expression by sponging miR-1297. Furthermore, SNHG6 knockdown repressed GC tumor growth in vivo. In a word, lncRNA SNHG6 knockdown had inhibitory effects on DDP resistance and progression of GC by sponging miR-1297, highlighting its potential in GC treatment.

Indexed as

Drug Resistance, NeoplasmAnimalsAntineoplastic AgentsCell Line, TumorCell MovementCell ProliferationCisplatinDisease ProgressionGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansMiceMice, NudeMicroRNAsNeoplasm InvasivenessProto-Oncogene Proteins c-bcl-2Antineoplastic AgentsBCL2 protein, humanCisplatinlong non-coding RNA SNHG6, humanMicroRNAsMIRN1297 microRNA, humanProto-Oncogene Proteins c-bcl-2RNA, Long NoncodingBCL-2cisplatin resistanceGastric cancerlncRNA SNHG6miR-1297

Identifiers

PMID34821362
PMCPMC8661508
OpenAlexW3216450308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.